European Viper Venom Proteins (Vipera aspis, Vipera ammodytes, Vipera latastei, and Vipera ursinii)

European viper venom proteins from Vipera aspis, Vipera ammodytes, Vipera latastei, and Vipera ursinii constitute a complex pharmacological arsenal used for prey immobilization and digestion. These venoms are primarily composed of enzymes such as phospholipases A2 (PLA2s), snake venom metalloproteinases (SVMPs), and snake venom serine proteases (SVSPs), alongside non-enzymatic proteins like C-type lectin-like proteins and disintegrins (Malina et al., 2017; Leonardi et al., 2019). Biologically, these proteins disrupt the hemostatic system, cause local tissue destruction, and, in the case of V. ammodytes and certain V. aspis populations, exert potent neurotoxic effects through presynaptic inhibition (Georgieva et al., 2017; Ferquel et al., 2007). In clinical medicine, these proteins are the therapeutic targets of polyvalent or monovalent antivenoms, which consist of purified F(ab')2 or Fab antibody fragments that bind and neutralize the toxins (WHO Guidelines, 2018). Beyond their role in envenomation, these proteins are of significant interest in drug discovery; for instance, disintegrins from these species have served as lead compounds for developing anti-thrombotic agents due to their ability to inhibit platelet aggregation (Calvete et al., 2005).

Other names

European viper venomVipera venom toxinsViperidae venom proteinsVipera aspis venomVipera ammodytes venomVipera latastei venomVipera ursinii venom

Neutralization of venom toxins through antibody-mediated binding, preventing interaction with physiological substrates and receptors.